DHR

In a comparison of two Medical Services stocks, Labcorp Holdings (LH) and Danaher (DHR), both holding a Zacks Rank #2 (Buy), Labcorp emerges as the superior value option. LH has a forward P/E of 17.67 and PEG ratio of 1.85, compared to DHR's 27.42 and 2.94 respectively. LH received a Value grade of B versus DHR's C grade, making it more attractive to value investors.

Several major companies exceeded third-quarter 2026 earnings expectations, driving positive stock movements. Capital One Financial surpassed estimates with $6.69 EPS, Bank OZK beat forecasts with $1.50 EPS, Thermo Fisher Scientific exceeded expectations with $6.68 EPS, and Danaher Corp. outperformed with $2.11 EPS.

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Danaher reported Q3 2026 earnings of $2.11 per share, beating consensus estimates of $1.92 and delivering a 9.90% earnings surprise. Revenue of $6.55 billion slightly exceeded expectations.

Despite the strong earnings beat, DHR shares have underperformed the S&P 500 by 14.4% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating, though the Medical Services industry ranks in the bottom 34% of sectors.

Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).

Zacks highlights two medical stocks with positive Earnings Surprise Prediction (ESP) figures that could beat upcoming earnings expectations. Danaher (DHR) has a +0.30% ESP with a #2 Buy rating ahead of October 21 earnings, while Guardant Health (GH) has a +13.19% ESP with a #2 Buy rating before November 5 earnings. Both stocks show potential for positive earnings surprises based on recent analyst revisions.

Danaher (DHR), an industrial and medical device maker, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 5.81%. The company's positive Earnings ESP of +0.30% combined with its Zacks Rank #2 (Buy) rating suggests another earnings beat is likely in its next quarterly report expected on October 21, 2026.

Danaher (DHR) is positioned as a likely earnings beat candidate for Q3 2026 with an Earnings ESP of +0.30% and Zacks Rank #2 (Buy). The company is expected to report EPS of $1.92 (up 1.6% YoY) and revenues of $6.55 billion (up 8.2% YoY). With a history of beating consensus estimates in the last four quarters, the stock appears well-positioned for positive price movement following its October 21 earnings release.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their quarterly earnings estimates. Regeneron (REGN) holds a #3 (Hold) rating with a +0.23% ESP ahead of its October 30, 2026 earnings release, while Danaher (DHR) has a #2 (Buy) rating with a +0.30% ESP before reporting on October 21, 2026. Both stocks show indicators suggesting potential positive earnings surprises.

Zacks Research Daily presents hand-picked analysis of 16 major stocks on October 7, 2026. AMD benefits from AI infrastructure demand but faces supply constraints.

Palo Alto Networks struggles with margin pressure and competition despite enterprise security consolidation trends. ConocoPhillips outperforms its industry with strong portfolio and LNG expansion, though commodity volatility poses risks. Additional coverage includes Danaher, Constellation Energy, Robinhood, and others with mixed outlooks.

Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).

SkinHealth Systems Inc. (SKIN) shares jumped 9% following completion of a 1-for-20 reverse stock split on October 14, 2026, which helped the company regain compliance with Nasdaq's minimum bid price requirement. However, the company faces significant headwinds with expected quarterly losses of $1.35 per share (down 1400% year-over-year) and revenues projected to decline 5% to $67.18 million. With no recent changes in earnings estimate revisions and a Zacks Rank #3 (Hold) rating, analysts question whether the recent rally can sustain.

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.

The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

Parker-Hannifin reported strong momentum in its Aerospace Systems segment with 13.3% organic sales growth and 18% order increases in fiscal Q4 2026. The company completed the acquisition of Filtration Group and has a pending deal for CIRCOR's aerospace business. However, rising operating expenses, $6.77 billion in long-term debt, and $401 million in annual interest expenses pose challenges to profitability.

The global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.

The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.